AD Blood Biomarkers in Diverse Community Settings: A Longitudinal Perspective From the ARIC Study

Chair(s)

• PP

  Priya Palta, PhD, MHS

  Associate Professor
  Neurology
  University of North Carolina
  Chapel Hill, North Carolina, United States

Co-Chair(s)

• KS

  Kevin Sullivan, PhD, MPH

  Assistant Professor
  Medicine
  University of Mississippi Medical Center
  Jackson, Mississippi, United States

Discussant(s)

• 

  Natascha Merten, PhD, MS (she/her/hers)

  Assistant Professor
  Department of Population Health Sciences and Department of Medicine
  University of Wisconsin-Madison
  Madison, Wisconsin, United States

Individual Symposium Abstract First Author(s)

• PP

  Priya Palta, PhD, MHS

  Associate Professor
  Neurology
  University of North Carolina
  Chapel Hill, North Carolina, United States
• KS

  Kevin Sullivan, PhD, MPH

  Assistant Professor
  Medicine
  University of Mississippi Medical Center
  Jackson, Mississippi, United States
• JP

  James Pike, MBA (he/him/his)

  Research Scientist
  Grossman School of Medicine
  New York University
  New York City, New York, United States
• BW

  B. Gwen Windham, MD, MHS

  Professor
  Medicine and Geriatrics
  University of Mississippi Medical Center - The MIND Center
  Jackson, Mississippi, United States

Alzheimer’s disease and related dementias (ADRD) feature a prolonged preclinical stage spanning decades, with the transition from mid- to late-life marking the critical period for onset and accumulation of pathological brain changes that may lead to physical and cognitive disability. Identifying individuals at risk for cognitive and physical decline during preclinical stages when interventions or disease modifying treatments are more likely to be effective is needed. Blood biomarkers of ADRD pathology and neurodegeneration are promising cost-effective and non-invasive options to fill this gap. To date, however, there are limited data on temporal changes in blood biomarkers and their associations with cognitive, mobility, and neuroimaging outcomes in diverse community-based cohorts. This symposium will feature 23 years of data from the well-established community-based Atherosclerosis Risk in Communities (ARIC) Study cohort which assayed blood biomarkers of amyloid-β (Aβ)42/40, phosphorylated tau at threonine 181 (p-Tau181), neurofilament light (NfL), and glial fibrillary acidic protein (GFAP) using Quanterix Simoa assays on stored specimens at up to 3 timepoints in midlife and late-life in ~1,800 participants. This session will present findings on temporal blood biomarker changes from mid- to late-life and associated risk and protective factors of biomarker changes; mid- to late-life changes in blood biomarkers and associations with late-life neuroimaging measures of neurodegeneration, cerebrovascular disease, and amyloid deposition; and the associations of late-life blood biomarkers with prevalent and incident mobility and cognitive impairment.

Presentations:

• 8:00 AM – 9:30 AM PST

  Design, Measures, and Correlates of Changes in AD Blood Biomarkers and Associations With Neuroimaging Outcomes
  

  Individual Symposium Abstract First Author: Priya Palta, PhD, MHS – University of North Carolina
• 8:00 AM – 9:30 AM PST

  Blood-Based Biomarkers for Alzheimer's Disease and Neurodegeneration in Relation to Incident Cognitive Status
  

  Individual Symposium Abstract First Author: Kevin J. Sullivan, PhD, MPH – University of Mississippi Medical Center
• 8:00 AM – 9:30 AM PST

  Change in Alzheimer's Disease Blood-Based Biomarkers and Associations With Brain Amyloid Deposition
  

  Individual Symposium Abstract First Author: James R. Pike, MBA (he/him/his) – New York University
• 8:00 AM – 9:30 AM PST

  AD/Neurodegeneration Blood Biomarker Associations With Prevalent and Incident Mobility and Cognitive Impairment
  

  Individual Symposium Abstract First Author: B. Gwen Windham, MD, MHS – University of Mississippi Medical Center - The MIND Center